|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Both approaches showed statistically significant decreased breast cancer risks for CASP8 D302H.
|
19367188 |
2009 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Association analysis identifies 65 new breast cancer risk loci.
|
29059683 |
2017 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Recent work from large consortial studies has led to the discovery of novel breast cancer susceptibility loci in genic (CASP8, FGFR2, TNRC9, MAP3K1, LSP1) and nongenic regions (8q24, 2q35, 5p12) of the genome, and to the finding of substantial heterogeneity by tumor characteristics.
|
19088016 |
2008 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that genetic variations in the promoter region of CASP8 gene, especially rs3834129, may serve as a genetic risk factor for breast cancer in an Iranian population.
|
31257627 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results thus suggest that the CASP8 5'-UTR C > T are associated with breast cancer risks and the effect may be modified by estrogen and progesterone receptor status.
|
17940865 |
2008 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer.
|
31467295 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
For Caucasians, CASP8-652 6N del was associated with reduced breast cancer risk at a borderline level (homozygous: OR=0.94, 95% CI 0.86-1.02, heterozygous: OR=0.96, 95% CI 0.90-1.03, recessive: OR=0.96, 95% CI 0.90-1.03, dominant: OR=0.94, 95% CI 0.88-1.01).
|
24457433 |
2014 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers.
|
17450141 |
2007 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
This study contributes to our understanding of CASP8 SNPs and breast cancer risk by subtype.
|
26758508 |
2016 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
The reproducible, dose-dependent association of CASP8 D302H with breast cancer indicates the potential importance of inherited variation in the apoptosis pathway in breast cancer susceptibility.
|
15601643 |
2004 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines.
|
26426685 |
2015 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer.
|
29915430 |
2018 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel.
|
25374178 |
2014 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
To clarify the role of CASP8 in breast cancer susceptibility, we carried out dense genotyping of this region in the Breast Cancer Association Consortium (BCAC).
|
25168388 |
2015 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Overall, Gag-CASP8-VLPs can deliver CASP8 into breast cancer cells, induce cell apoptosis, and inhibit tumor growth.
|
30620218 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
CASP8 -652 6N del was associated with reduced breast cancer risk at a borderline level (for del carriers: pooled OR = 0.884, 95% CI: 0.761-1.028); the power calculation pointed to lack of power in the individual studies.
|
19629679 |
2010 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
We found evidence of an association with breast cancer for CASP8 D302H (with odds ratios (OR) of 0.89 (95% confidence interval (c.i.): 0.85-0.94) and 0.74 (95% c.i.
|
17293864 |
2007 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We confirmed previous associations between increased breast cancer risk and SNPs in CASP8, TOX3 (previously known as TNRC9) and ESR1.
|
19094228 |
2008 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Impaired kinetics of Bax-GFP and Smac/DIABLO-GFP in caspase-8- and bid-silenced and Bcl-2 overexpressed breast cancer MCF-7 cells exposed to camptothecin.
|
17666167 |
2007 |
|
Breast Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
The CpG sites in the promoter region of CASP8 and maspin were methylated in all four breast cancer cell lines but not in two non-tumorigenic breast cell lines.
|
20132554 |
2010 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We observed an allele-dose dependent association between CASP8 -652 6N InsDel and caspase 8 mRNA expression in breast cancer tissue, with homozygous deletion carriers showing lowest relative caspase 8 expression (p = 0.0131).
|
27507139 |
2016 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
AMR-Me induced DNA fragmentation and PARP degradation which were preceded by changing Bax/Bcl-2 ratios, cytochrome c release, and subsequent induction of pro-caspase-9 and -7 processing in breast carcinoma MCF-7 cells, but it did not act on Fas/Fas ligand pathways and the activation of caspase-8, suggesting AMR-Me triggered the mitochondrial apoptotic pathway.
|
18058803 |
2008 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
High caspase-3 expression, but not caspase-8, is significantly associated with adverse breast cancer-specific survival (P = 0.008 and P = 0.056, respectively).
|
27798717 |
2017 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway.
|
21854868 |
2011 |